Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Leukemia

Do you want to read an article? Please log in or register.

Reference

Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis YK, Yates B, Morales Arana A, Shouval R, Curran KJ, Gardner RA, Shalabi H, Annesley C, Park JH, Subklewe M, Shah NN

Blood.
2024 Nov 19.
doi: 10.1182/blood.2024025910.

Visit the original publication at ncbi.nlm.nih.gov

Reference

Related content

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

A novel bicistronic CD19/CD22 CAR T-cell therapy is effective and safe in children with relapsed or refractory B-ALL

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma